Research Alliance II (Research Alliance II) 3-Year EBITDA Growth Rate : 0.00% (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Research Alliance II 3-Year EBITDA Growth Rate?

Research Alliance II's EBITDA per Share for the three months ended in Sep. 2022 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Competitive Comparison of Research Alliance II's 3-Year EBITDA Growth Rate

For the Shell Companies subindustry, Research Alliance II's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Research Alliance II's 3-Year EBITDA Growth Rate Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Research Alliance II's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Research Alliance II's 3-Year EBITDA Growth Rate falls into.

Research Alliance II 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Research Alliance II (NAS:RACB) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Research Alliance II 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Research Alliance II's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Research Alliance II (Research Alliance II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Research Alliance Corp II (NAS:RACB) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

3172 North Rainbow Boulevard, Suite 1278, Las Vegas, NV, USA, 89108

Website

https://www.researchalliancecorp.com

Research Alliance Corp II is a blank check company.

Executives

Saba Capital Management, L.p.	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Peter Kolchinsky	director, officer: Chief Executive Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Stephen J Hoffman	director	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Thomas Leggett	director	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Matthew Hammond	director, officer: Chief Investment Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Research Alliance Holdings Ii Llc	10 percent owner	200 BERKELEY STREET 18TH FLOOR, BOSTON MA 02116
Theresa Cameron	director, 10 percent owner, officer: Chief Financial Officer	C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Clive Patience	director	C/O RESEARCH ALLIANCE CORP. II, 3172 NORTH RAINBOW BLVD. SUITE 1278, LAS VEGAS NV 89108

Research Alliance II (Research Alliance II) Headlines

From GuruFocus

Research Alliance Corp. II Will Redeem Public Shares

By Business Wire Business Wire • 11-28-2022

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

By Business Wire Business Wire • 04-28-2021